

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

CHINA PHARMA HOLDINGS, INC.
Form 10QSB
May 15, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2006

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _____ to _____

Commission file number: 000-29523

China Pharma Holdings, Inc.
(Exact name of registrant as specified on its charter)

Delaware 73-1564807
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China
(Address of principle executive offices)

0086-898-66811730 (China) 858-776-8880 (USA)
(Registrant's telephone number, including area code)

Copies to:

Charles Law
King and Wood LLP
650 Page Mill Road,
Palo Alto, CA 94304

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS:

State the number of shares outstanding of each of the registrant's classes of common equity, as of the latest practicable date: 34,723,056 shares of common

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

stock issued and outstanding as of March 31, 2006.

Transitional Small Business disclosure format: Yes [] No [X]

China Pharma Holdings, Inc.

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

ITEM 1	Financial Statements	F-1thruF-8
ITEM 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	1-6
ITEM 3	Controls and Procedures	6

PART II OTHER INFORMATION

ITEM 1	Legal proceedings	7
ITEM 2	Unregistered Sales of Equity Securities and use of proceeds	7
ITEM 3	Defaults upon senior securities	7
ITEM 4	Submission of matters to a vote of security holders	7
ITEM 5	Other information	8
ITEM 6	Exhibits and Reports on 8-K	8

SIGNATURES	9
------------	---

EXHIBITS

=====

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Part I - FINANCIAL INFORMATION

Item 1. Financial Statements

	Page ----
TABLE OF CONTENTS	
Condensed Consolidated Balance Sheets (unaudited), March 31, 2006 and December 31, 2005	F-1
Condensed Consolidated Statements of Operations (unaudited), for the three months ended March 31, 2006 and from January 12, 2005 (Date of Inception) through March 31, 2005	F-2
Condensed Consolidated Statements of Cash Flows (unaudited), for the three months ended March 31, 2006 and from January 12, 2005 (Date of Inception) through March 31, 2005	F-3
Notes to Condensed Consolidated Financial Statements (unaudited)	F-4 thru F-8

Item 1. Financial Statements

CHINA PHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

	March 31, 2006	December 31, 2005
ASSETS		
Current assets		
Cash and cash equivalents	\$ 74,924	\$ 461,220
Trade accounts receivables, less allowance for doubtful accounts of \$1,168,385 and \$1,412,353, respectively	8,251,166	5,709,762
Other non-trade receivables, less allowance for doubtful accounts of \$64,439 and \$111,029, respectively	682,821	385,957
Advances to suppliers	1,722,661	2,123,729
Inventory	6,550,268	5,785,196
	-----	-----
Total current assets	17,281,840	14,465,864
	-----	-----
Non-current assets		
Property and equipment, net	2,757,705	2,808,342

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Intangible assets, net	86,597	96,406
Deferred tax assets	156,350	130,458
	-----	-----
Total non-current assets	3,000,652	3,035,206
	-----	-----
Total assets	\$ 20,282,492	\$ 17,501,070
	=====	=====
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Trade accounts payable	\$ 1,407,145	\$ 679,104
Accrued expenses	32,090	15,625
Taxes payable	937,492	565,236
Other accounts payable	206,048	250,317
Advances from customers	50,491	50,755
Short-term notes payable	4,240,914	--
Dividends payable	--	4,209,889
	-----	-----
Total current liabilities	6,874,180	5,770,926
	-----	-----
Long-term liabilities		
Research and development commitment	31,113	30,966
	-----	-----
Total long-term liabilities	31,113	30,966
	-----	-----
Shareholders' equity		
Common shares - \$0.001 par value; 60,000,000 shares authorized; 34,723,056 shares issued and outstanding	34,723	34,723
Additional paid-in capital	7,764,979	7,764,979
Accumulated other comprehensive income	159,011	99,926
Retained earnings	5,418,486	3,799,550
	-----	-----
Total shareholders' equity	13,377,199	11,699,178
	-----	-----
Total liabilities and shareholders' equity	\$ 20,282,492	\$ 17,501,070
	=====	=====

The accompanying notes are an integral part of the financial statements

F-1

CHINA PHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

For the three
months ended
March 31, 2006

For the period fr
January 12, 2005
(Date of Inceptio
through
March 31, 2005

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Revenues	\$	4,732,991	\$	--
Cost of revenues		2,526,020		--
		-----		-----
Gross profit		2,206,971		--
		-----		-----
Operating expenses				
Selling expenses		88,030		--
General and administrative		264,200		--
		-----		-----
Total operating expenses		352,230		--
		-----		-----
Income from operations		1,854,741		--
		-----		-----
Non-operating income (expenses)				
Interest income		147		--
Interest expense		(23,799)		--
Other income (expenses)		22,636		--
		-----		-----
Non-operating income (expenses)		(1,016)		--
		-----		-----
Income before taxes		1,853,725		--
Income tax expense		234,789		--
		-----		-----
Net income		1,618,936		--
		-----		-----
Comprehensive Income - currency translation adjustment		59,085		--
		-----		-----
Comprehensive Income	\$	1,678,021		--
		=====		=====
Basic and diluted earnings per common share	\$	0.05	\$	--
		=====		=====
Weighted-average common shares outstanding		34,723,056		--
		=====		=====

The accompanying notes are an integral part of the financial statements
F-2

CHINA PHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

	For the period from January 12, 2005 (Date of Inception) through March 31, 2005
For the three months ended March 31, 2006	
-----	-----

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Cash flows from operating activities			
Net income	\$	1,618,936	\$ --
Depreciation and amortization		85,140	--
Changes in assets and liabilities:		--	
Accounts receivable		(2,541,404)	--
Other receivable		(296,864)	--
Advances to suppliers		401,068	--
Inventory		(765,072)	--
Deferred tax asset		(25,892)	--
Trade accounts payable		728,040	--
Other accounts payable		(44,269)	--
Accrued expenses		16,465	--
Advances from customers		(264)	--
Accrued taxes payable		372,256	--

Net cash used in operating activities		(451,860)	--

Cash Flows from Investing Activities			
Purchase of property and equipment		(22,074)	--
Purchase of intangible assets		(2,472)	--

Net cash used by investing activities		(24,546)	--
Effect of exchange rate changes in cash		90,110	--

Net decrease in cash		(386,296)	--
Cash and cash equivalents at beginning of period		461,220	--

Cash and cash equivalents at end of period	\$	74,924	\$ --
		=====	=====

The accompanying notes are an integral part of the financial statements

F-3

CHINA PHARMA HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2006
(unaudited)

NOTE 1 - Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of China Pharma Holding, Inc. (the "Company"); formerly known as TS Electronics, Inc., and its subsidiaries were prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

America have been condensed or omitted pursuant to such rules and regulations. Management of the Company ("Management") believes that the following disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company's Form 10-K report for the year ended December 31, 2005.

These unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of Management, are necessary to present fairly the consolidated financial position and results of operations of the Company for the periods presented. Operating results for the three months ended March 31, 2006, are not necessarily indicative of the results that may be expected for the year ending December 31, 2006.

Organization - Onny Investment Limited ("Onny") was incorporated in the British Virgin Islands on January 12, 2005. Through June 15, 2005, Onny was a development stage enterprise with no activities except for the acquisition of Hainan Helpson Medical & Biotechnology Co., Ltd ("Helpson"), as discussed below. Upon the acquisition of Helpson and its operations, Onny emerged from the development stage. On June 16, 2005, Onny acquired all of the outstanding shares of Helpson and emerged from the development stage.

On October 19, 2005, Onny was reorganized as a wholly-owned subsidiary of the Company. The reorganization was accomplished through the exchange of 29,700 shares of Onny common stock for 20,555,329 shares of the Company's common stock and for the commitment of the Company to issue an additional 4,723,056 shares upon amending its articles of incorporation. The exchange of shares was a 851-for-1 exchange ratio. In addition, the prior Onny preferred shareholders exchanged their 10,000 shares of Onny common stock for 6,944,611 shares of the Company's common stock for a 694-for-1 exchange ratio. Additionally, the prior Onny preferred shareholders converted their preferred stock into Onny common

F-4

shares. The reorganization of Onny into the Company was recognized as a stock split of the common stock of Onny and the effective issuance by Onny of 2,500,060 shares of common stock to the Company's pre-reorganization shareholders and the assumption of \$4,473 of liabilities. The reverse acquisition of the Company was recognized as a non-monetary exchange.

During the period ended March 31, 2006, the Company amended its articles of incorporation to increase its authorized shares from 30,000,000 shares to 60,000,000 shares.

Nature of Operations - Helpson manufactures and markets several Western and Chinese medicines sold mainly to hospitals and private retailers in The People's Republic of China (PRC). The marketing department is in Hainan Province and there are also nine offices with sales representative in other provinces and cities throughout the PRC. Helpson's other operating activities include biochemical products, health products, and cosmetics.

Accounting Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Basic and Diluted Earnings per Common Share - Basic and diluted earnings per common share are computed by dividing net income by the weighted-average number of common shares outstanding. There were no dilutive common shares outstanding on March 31, 2006.

NOTE 2 - Acquisition

On May 25, 2005, Onny entered into an agreement with the shareholders of Helpson, a privately held PRC joint venture, in which Onny agreed to acquire and the shareholders of Helpson agreed to sell, all of the outstanding common shares of Helpson in exchange for the assumption of obligations to make cash payments to the Helpson shareholders in the form of common stock dividends from Helpson of \$4,154,041 the assumption of \$4,646,409 of other liabilities and the issuance of non-interest bearing promissory notes totaling \$3,413,265 payable three months after Helpson obtains a business license in the PRC as a wholly foreign owned entity. Helpson obtained such license on June 16, 2005 and the shares of Helpson were transferred to Onny on that date. Since June 16, 2005 was recognized as the date of the acquisition, the promissory notes became due September 16, 2005.

Since Helpson is an operating company and control of Helpson changed upon the closing of the acquisition agreement, Onny is the accounting acquirer and has recognized the acquisition of Helpson as a business combination in accordance

F-5

with Statements of Financial Accounting Standards No. 141, Business Combinations. On April 25, 2005, Helpson declared a dividend to the selling shareholders of \$4,154,041 which equaled Helpson's retained earnings at March 31, 2005 less deferred income tax assets of \$86,985 that are not considered part of distributable profits under PRC law. The fair value of the net assets of Helpson was determined by appraisal. The cost of the net assets exceeded the fair value. That excess was allocated as a pro-rate reduction of the amounts that otherwise would have been assigned to the non-current assets acquired.

NOTE 3 - Inventory

Inventory consisted of the following as of March 31, 2006:

Raw Materials	\$ 4,605,479
Work In Process	457,826
Finished Goods	1,486,963

	\$ 6,550,268
	=====

NOTE 4 - Income Taxes

The Company accounts for its income taxes in accordance with Statement of Financial Accounting Standards No. 109, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and any tax credit carry forwards available. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

period that includes the enactment date. Helpson received tax benefits as a result of a reduced tax rate from 30% to 15%, as a result of being in the first five years of operations and a reduced tax of 7.5% as a result of operating in a developing economic area in the PRC. The 7.5% enterprise income tax rate was applied to the pre-tax income with the following result:

F-6

	For the three months ended March 31, 2006	For the period from January 12, 2005 (Date of Inception) through March 31, 2005
Tax at US Federal statutory rate (34%)	\$ 630,267	\$ --
Non-deductible expenses	(1,648)	--
Change in temporary differences	79,826	--
Effect of lower foreign tax rates	(473,656)	--
Income tax provision	\$ 234,789	\$ --

The Company has a deferred tax asset based upon the temporary differences from the allowance for bad debt that equals \$156,350. The Company has also incurred various other taxes, primarily comprised of business tax, value-added tax, urban construction tax, education surcharges and etc. Any unpaid amounts are reflected on the balance sheets as other taxes payable.

NOTE 5 - Short Term Notes Payable

In January 2006, the Company reclassified its dividends payable as short term notes and commenced accruing interest on the amount due at a rate of 2.25% per annum, resulting in interest expense of \$23,799 at March 31, 2006.

NOTE 6 - Stockholders' Equity

On October 19, 2005, the Company acquired all of the issued and outstanding common stock of Onny; thus, Onny became a wholly owned subsidiary of the Company. The reorganization of Onny into the Company was recognized as a stock split of the common stock of Onny and the effective issuance by Onny of 2,500,060 shares of common stock to the Company's pre-reorganization shareholders. The number of common shares issued and outstanding has been restated in the accompanying condensed consolidated financial statements on a retroactive basis for the effects of the stock split.

NOTE 7 - Contingencies

Economic environment - Significantly all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and foreign currency exchange. The Company's results may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

F-7

In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi ("RMB" or "(Y)"), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

F-8

Item 2. Management's Discussion and Analysis or Plan of Operation

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto and the other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain certain forward-looking information. Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. When used in this discussion, the words "believes," "anticipates," "expects," and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those projected due to a number of factors beyond our control.

We do not undertake to publicly update or revise any of the forward-looking statements even if experience or future changes show that the indicated results or events will not be realized. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. You are also urged to carefully review and consider our discussions regarding the various factors, which affect our business, included in this section and elsewhere in this report.

Factors that might cause actual results, performance or achievements to differ

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

material, among other things: lay from those projected or implied in such forward-looking statements include: (i) the impact of competitive products; (ii) changes in law and regulations; (iii) adequacy and availability of insurance coverage; (iv) limitations on future financing; (v) increases in the cost of borrowings and unavailability of debt or equity capital; (vi) the effect of adverse publicity regarding our products; (vii) our inability to gain and/or hold market share; (viii) exposure to and expense of resolving and defending product liability claims and other litigation; (ix) consumer acceptance of our products; (x) managing and maintaining growth; (xi) customer demands; (xii) market and industry conditions including pricing and demand for products, (xiii) the success of product development and new product introductions into the marketplace; (xiv) the departure of key members of management; (xv) our ability to efficiently market our products; as well as other risks and uncertainties that are described from time to time in our filings with the Securities and Exchange Commission.

Notwithstanding the above, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to companies that issue securities that meet the definition of a penny stock, as such, the safe harbor for forward looking statements does not apply to us.

1

Overview

On June 16, 2005, Onny Investment Limited ("Onny") acquired all of the outstanding common shares of Hainan Helpson Medical Biotechnology Co., Ltd ("Helpson"), a privately held Chinese joint venture, in exchange for common stock dividends payable to the Helpson shareholders of \$4,154,041 and for non-interest bearing promissory notes totaling \$3,413,265 payable on September 16, 2005. The acquisition of Helpson was recognized as a business combination.

On October 19, 2005, Onny issued 10,000 preferred shares in exchange for \$4,313,000 in cash, net of offering costs and estimated registration costs, and on that same date, those preferred shares were converted into 10,000 Onny common shares. Also on October 19, 2005, Onny was reorganized as a wholly-owned subsidiary of China Pharma Holdings, Inc. The reorganization was accomplished by the original Onny common shareholder exchanging her 29,700 Onny common shares for 20,555,329 common shares of China Pharma Holdings, Inc. and for the commitment by China Pharma Holdings, Inc. to issue the original Onny common shareholder 4,723,056 common shares following an amendment of the China Pharma Holdings, Inc.. articles of incorporation increasing the number of common shares authorized to 60,000,000 shares. In addition, the prior Onny preferred shareholders exchanged their 10,000 Onny common shares for 6,944,611 common shares of China Pharma Holdings, Inc.

We launched an anti-flu product named PuSenOK, which is the only anti flu medicine in the market mixed with pseudo ephedrine hydrochloride, that has a non-drowsy formula and a runny nose suppressant. We plan to expand our biotechnology product series. Based on the foundation established by some of Helpson's widely recognized medicine labels such as Neurotrophicpeptide, we will launch several additional biological medicines, including the brain peptide injection, injected hepatocyte growth-promoting factors, as well as new genetic medicines, rh-CNTF and rha-FGF, which will give us a new growth following that of Neurotrophicpeptide.

Our products have been sold in more than 20 provinces, sovereignties, and autonomous regions. We have 16 sales offices and approximately 250 proxy agents

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

in the whole country. The main channels we use to deliver our products were as follows: (1) Distribution system (Proxy Agency); (2) Direct sale system to hospitals; (3) Direct representation in clinic hospitals through medical representatives; and (4) Distribution of products to local medical companies through logistics companies.

Our recent business activities include the following:

2005: Helpson launched a new anti-flu medicine: PusenOK.

2003: Helpson gained GMP authentication.

2003: Helpson named "the best enterprise for storing SARS medicine" by Hainan Food and Drug Administration.

2000: Helpson awarded as one of 50 best enterprises in Hainan by Hainan Economic and Trade Bureau and Hainan Statistical Bureau.

2

Buflomedil Hydrochloride (Raw material; injection; & troche)

- o Received the best technology commercialization award in Hainan in 2004 by Hainan Scientific and Technological Result Examination Committee.
- o Received the national key new products certificate in 2003 by the State Science and Technology Department, State Taxation Bureau, Ministry of Commerce, State Bureau of Quality Supervision, Inspection and Quarantine, and State Environmental Protection Bureau.
- o Designated as the key technology project in Hainan in 2003 by Haikou Municipality.

Operations Analysis For the three months ended
March 31, 2006

The following table presents the operation of the Company for the three months ended March 31, 2006:

	For the three months ended March 31, 2006
Revenues	\$ 4,732,991
Cost of revenues	\$ 2,526,020
Operating expenses	\$ 352,230
Income from operations	\$ 1,854,741
Interest expense	\$ 23,799
Net income	\$ 1,618,936
Basic and diluted earnings per common share	\$ 0.05

Revenues

Revenues were \$4,732,991 for the three months ended March 31, 2006. During this period, the revenues increased rapidly, the reasons of which mainly are as follows:

Firstly, the promotion of products has obtained an apparent effect, which resulted in that the new products have quickly entered the market. The above new products primarily include Gastrodin injection and Naproxen Sodium and Pesudophedrine Hydrochloride (or Pusen OK). Secondly, the sales network has spread over the majority of provinces in China. Lastly, increased outputs of products ensured a significant improvement in sales since the manufacturing capacity of Helpson has been expanded.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Cost of Revenues

The cost of revenues was \$2,526,020, which is 53% of the revenues.

3

The two new products, which have higher gross profit margins, were introduced into the market. Thus, the cost of revenues was reduced during the period due to an increased sale. The cost is expected to be further reduced due to economies of scale caused by the expected rapid growth of the company, the effective cost control and the improvement of the manufacturing process in the year 2006.

Operating expenses

The operating expenses for the three months ended March 31, 2006 were \$352,230, which is 18.99% of income from operations.

The selling expenses include the welfare and salaries of the sales person and related transportation expenses. The selling expenses compared with revenue are lower than the industry average level, the main reasons for that are its major customers are hospitals and the selling network of the company is through agents. However, the company incurred some advertising expenses to promote its new product PuSen OK, which increased the percentage of selling expenses compared to the revenues in 2006.

The general and administrative expenses include R&D, the welfare and salaries of the administrative staff. Compared with the R&D expenditure in 2005, the amount of the R&D expenditure for new products was decreased because the researchers come from company personnel. Meanwhile, the reduced amortization of intangible assets was another reason causes a decreased operating expense.

Income from operations was \$1,854,741, which is 39% of the total revenues.

Interest expenses

Interest expense for three months ended March 31, 2006 is \$23,799 and net income is \$1,618,936. The Company just paid off two long-term loans in 2005, but the Company had not applied for new loans up to March 31, 2006, which made a significant decrease of interest expenses during the first quarter of 2006. However, the Company plans to apply for a new loan of approximately \$3,130,000 in May of 2006. The expected annual interest rate is 6% will cause an increase in interest expenses later.

Helpson is now applying for a special tax policy, which is for the foreign companies in China. The policy is that the qualified foreign companies do not have to pay income taxes in the first two years of their operations in China. From the third to the fifth year, the companies only need to pay half of the income tax rate 15%, which is 7.5%. As a new foreign company, it is supposed to be approved as tax exemption in the year 2006. Since the application was in process, the Company still needed to pay income tax during the first quarter of 2006. However, the above income tax is anticipated to be paid back by Chinese government as soon as the favorable tax policy is authorized in the late of year 2006.

4

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Liquidity and capital resource for the three months ended March 31, 2006

The following table presents selected items from the balance sheets as of March 31, 2006, and December 31, 2005

	As of March 31, 2006	As of December 31, 2005
	2006	2006
cash and cash equivalents	\$ 74,924	\$ 461,220
trade accounts receivable	\$ 8,251,166	\$ 5,709,762
inventory	\$ 6,550,268	\$ 5,785,196
Total current assets	\$ 17,281,840	\$ 14,465,864
property and equipment, net	\$ 2,757,705	\$ 2,808,342
total assets	\$ 20,282,492	\$ 17,501,070
Total current liabilities	\$ 6,874,180	\$ 5,770,926
long-term liabilities	\$ 31,113	\$ 30,966
Total shareholder's equity	\$ 13,377,199	\$ 11,699,178

Analysis of financial position

At March 31, 2006, cash and cash equivalents of \$74,924, which were 4.34% of the total current assets, were decreased by 83.76% compared to the same item at December 31, 2005. The net value of property and equipment was \$ 2,757,705, 13.6% of the total assets.

The trade accounts receivables were \$8,251,166 and the valuation of inventory was \$6,550,268 at March 31, 2006. Trade accounts receivable and inventory amounted to 40.7% and 32.3% respectively of the total assets. The dramatic increase of sales revenues from the subsidiary of TS in China, Helpson, caused the increase of the value of trade receivables. The long collection period of accounts receivable also caused that the accounts receivable was increased by 44.51% compared with at December 31, 2005. Considering the slow collectibility, the Company plans to pay more attention to collecting trade accounts receivable, try to use cash-sales when selling products to new customers or small-sized customers.

5

An increase of 13.22% in inventory was primarily due to the special geographical location of Hainan Island, there is a long distance from other provinces causing some difficulties of transportation of inventory, and the Company has to prepare more materials in order to satisfy the production demands. Secondly, some of the materials need to be produced by specific manufacturers; the company has to save the materials to meet the demands of production. Moreover, a dramatically increased sale resulted in a rise of inventory.

The total liabilities of \$6,905,293 compared with total assets of \$20,282,492, results in a liability ratio of 34.05%. If the inventory of \$6,550,268 is excluded from total current assets of \$17,281,840, compared with the current liabilities of \$6,874,180, result in a quick ratio of 1.56. This shows that the Company has ability to pay its debts.

An increase of \$1,678,021, 14.34% in the shareholder's equity compared to at December 31, 2005 is primarily due to the increase of accumulated other comprehensive income, and the increase of the retained earnings which was caused by the increased sales revenue.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Operating activities

As of March 31, 2006 we had cash and cash equivalents in the amount of \$74,924, which was decreased by 83.76%, in the amount of \$386,296, compared to at December 31, 2005. Net cash flow used in operating activities during the first quarter of 2006 was \$451,860. The main reason for the amount in cash utilized in operating activities was an increase of trade accounts receivable in the amount of \$2,541,404, and an increase of inventory in the amount of \$765,072 during the period.

Investing activities

Net cash utilized in investing activities was \$24,546 during the first quarter of 2006. The use of net cash was due to the purchase of PPE (Construction in progress) and intangible assets which amounted to \$22,074 and \$2,472, respectively.

In conclusion, cash utilized for the first quarter amounted to \$386,296, primarily due to the net cash used in operating activity in the amount of \$451,860, and the decrease of net cash flow in the purchase of long-term assets in the amount of \$24,546.

Item 3 - Control and Procedures

As required by Rule 13a-15 under the Exchange Act, within the 90 days prior to the filing date of this report, the Company carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls

6

and procedures. This evaluation was carried out under the supervision and with the participation of the Company's management, including the Company's President and Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, the Company's President and Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective. There have been no significant changes in the Company's internal controls or in other factors, which could significantly affect internal controls subsequent to the date the Company carried out its evaluation.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in Company reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in Company reports filed under the Exchange Act is accumulated and communicated to management, including the Company's Chief Executive and Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure.

PART II. OTHER INFORMATION

Item 1 Legal Proceedings

From time to time, we may become involved in various lawsuits and legal

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceeding or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3 - Defaults upon Senior Securities

Not Applicable.

Item 4 - Submission of Matters to a Vote of Security Holders

On March 28, 2006, the Company filed a form definitive 14C to effect the followings:

7

- o Change our corporate name from TS Electronics, Inc. to China Pharma Holdings, Inc.;
- o Increase the number of shares of common stock authorized to be issued by the corporation from Thirty Million (30,000,000) shares to Sixty Million (60,000,000) shares; and
- o Set the number of directors constituting the entire Board of Directors at between three and nine, with the specific number to be fixed from time to time by a vote of the majority of the entire Board of Directors.

The definitive 14C became effective on May 1, 2005 when the Company filed its Amended Certificate of Incorporation with the Secretary of the State of Delaware.

Item 5 - Other Information

None.

Item 6 - Exhibits and Reports on Form 8-K

(a) Exhibits

31.1 - Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.

31.2 - Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.

32.1 - Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 - Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10QSB

Sarbanes-Oxley Act of 2002.

8

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

China Pharma Holdings, Inc.

Dated: May 11, 2006

By: /s/ Zhilin Li
Chief Executive Officer,
President and Director

Dated: May 11, 2006

By: /s/ Xinhua Wu
Chief Financial Officer
and Director

9